GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jiangsu Sinopep Allsino Biopharmaceutical Co 688076.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

27.90

+1.31%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jiangsu Sinopep Allsino Biopharmaceutical Co

Its shares trade on Shanghai under the ticker 688076.SS. It has been listed since 20 May 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.94bn and net income of CN¥327.0m. At that date it held total assets of CN¥6.74bn and shareholders' equity of CN¥2.99bn.

Sinopep-Allsino Bio Pharmaceutical Co., Ltd. engages in the research and development, and manufacture of pyropolypeptide and small molecule drugs. The company is headquartered in Lianyungang, Jiangsu. The company went IPO on 2021-05-20. The firm's main businesses include customized product businesses and self-selected businesses. Its customized product businesses include CDMO (Contract Development and Manufacturing Organization) business, CMO (Custom Manufacturing Organization) business and technical service and transfer business. Its self-selected products include Active Pharmaceutical Ingredients (API), intermediates and preparations. The firm operates its businesses both in the domestic market and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
20 May 2021
Employees
1,114

Leadership

Pay as last reported

  • Mr. Tangqing LiDeputy General Manager
  • Mr. Xiaohua LiDeputy General Manager

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Jiangsu Sinopep Allsino Biopharmaceutical employs 1114 employees for research and development.
  • Lianyungang headquarters supports domestic and overseas market operations.
  • Customized product businesses include CDMO and CMO services.

Weaknesses

  • The company's IPO date is 20 May 2021, which is recent.
  • Self-selected products include API, intermediates, and preparations.
  • The firm operates in the Health Care sector with limited diversification.

Opportunities

  • The company's CDMO business can expand in the global pharmaceutical market.
  • Overseas market operations present growth potential for self-selected products.
  • Domestic market presence supports stable revenue streams.

Threats

  • The Health Care sector faces increasing regulatory challenges in China.
  • Pharmaceutical industry competition intensifies with new entrants.
  • Overseas market operations encounter geopolitical risks.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.